The historical rank and industry rank for Novelion Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
NVLNF's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.65 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Novelion Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Novelion Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novelion Therapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Novelion Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novelion Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Novelion Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Novelion Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Novelion Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Novelion Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Novelion Therapeutics (Novelion Therapeutics) Business Description
Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NVLNF has been successfully added to your 